What is the appropriate meropenem MIC for screening of carbapenemase-producing Enterobacteriaceae in low-prevalence settings?

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1556-1559

  Fattouh, Ramzi ^a   Tijet, Nathalie ^b   McGeer, Allison ^a,c   Poutanen, Susan M ^a,c   Melano, Roberto G ^a,b   Patel, Samir N ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PUBLIC HEALTH ONTARIO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE KPC; BETA LACTAMASE NDM; BETA LACTAMASE OXA 48; CARBAPENEMASE; ERTAPENEM; MEROPENEM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAM; BETA LACTAMASE; BETA-LACTAMASE OXA-48, E COLI; ESCHERICHIA COLI PROTEIN; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CITROBACTER; ESCHERICHIA COLI; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECTS; ENTEROBACTER; ENTEROBACTERIACEAE INFECTIONS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; ENTEROBACTER; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; MULTIPLEX POLYMERASE CHAIN REACTION; THIENAMYCINS;

EID: 84960155211     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02304-15     Document Type: Article

References (28)

1. Patel G, Bonomo RA. 2013. "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol 4:48. http://dx.doi.org/10.3389/fmicb.2013.00048.
2. van Duin D, Kaye KS, Neuner EA, Bonomo RA. 2013. Carbapenemresistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 75:115-120. http://dx.doi.org/10.1016/j.diagmicrobio.2012.11.009.
3. Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, Skoutelis A, Georgousi K, Tzouvelekis LS, Tassios PT, Bamia C, Petrikkos G. 2009. Prospective observational study of the impact of VIM-1 metallobetalactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 53:1868-1873. http://dx.doi.org/10.1128/AAC.00782-08.
4. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. 2009. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae. Infect Control Hosp Epidemiol 30:1180-1185. http://dx.doi.org/10.1086/648451.
5. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099-1106. http://dx.doi.org/10.1086/592412.
6. Centers for Disease Control and Prevention. 2012. CRE toolkitguidance for control of carbapenem-resistant Enterobacteriaceae (CRE). Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/hai/organisms/cre/cre-toolkit/index. Accessed 2 October 2015.
7. CLSI. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. CLSI, Wayne, PA.
8. Cohen Stuart J, Leverstein-Van Hall MA, Dutch Working Party on the Detection of Highly Resistant Microorganisms. 2010. Guideline for phenotypic screening and confirmation of carbapenemases in Enterobacteriaceae. Int J Antimicrob Agents 36:205-210. http://dx.doi.org/10.1016/j.ijantimicag.2010.05.014.
9. Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G. 2013. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141-160. http://dx.doi.org/10.1111/j.1469-0691.2011.03703.x.
10. Giske CG, Martinez-Martinez L, Canton R, Stefani S, Skov R, Glupczynski Y, Nordmann PN, Wootton M, Miriagou V, Simonsen GS, Zemlickova H, Cohen-Stuart J, Gniadkowski M. 2013. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. http://www.eucast.org/resistance-mechanisms/.
11. Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V, European Network on Carbapenemases. 2012. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 18:432-438. http://dx.doi.org/10.1111/j.1469-0691.2012.03815.x.
12. Vading M, Samuelsen O, Haldorsen B, Sundsfjord AS, Giske CG. 2011. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemaseproducing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. Clin Microbiol Infect 17:668-674. http://dx.doi.org/10.1111/j.1469-0691.2010.03299.x.
13. Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, Carey RB, Thompson A, Stocker S, Limbago B, Patel JB. 2007. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 45:2723-2725. http://dx.doi.org/10.1128/JCM.00015-07.
14. Doumith M, Ellington MJ, Livermore DM, Woodford N. 2009. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 63:659-667. http://dx.doi.org/10.1093/jac/dkp029.
15. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. 2010. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother 65:490-495. http://dx.doi.org/10.1093/jac/dkp498.
16. Tijet N, Alexander DC, Richardson D, Lastovetska O, Low DE, Patel SN, Melano RG. 2011. New Delhi metallo-beta-lactamase, Ontario, Canada. Emerg Infect Dis 17:306-307. http://dx.doi.org/10.3201/eid1702.101561.
17. Dortet L, Poirel L, Nordmann P. 2012. Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using a biochemical test. Antimicrob Agents Chemother 56:6437-6440. http://dx.doi.org/10.1128/AAC.01395-12.
18. Endimiani A, Perez F, Bajaksouzian S, Windau AR, Good CE, Choudhary Y, Hujer AM, Bethel CR, Bonomo RA, Jacobs MR. 2010. Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. J Clin Microbiol 48:4417-4425. http://dx.doi.org/10.1128/JCM.02458-09.
19. Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, LaBombardi VJ, Nicolau DP, Kuti JL. 2010. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 48:2402-2406. http://dx.doi.org/10.1128/JCM.00267-10.
20. Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A. 2009. Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. J Clin Microbiol 47:1631-1639. http://dx.doi.org/10.1128/JCM.00130-09.
21. Arana DM, Saez D, Garcia-Hierro P, Bautista V, Fernandez-Romero S, Angel de la Cal M, Alos JI, Oteo J. 2015. Concurrent interspecies and clonal dissemination of OXA-48 carbapenemase. Clin Microbiol Infect 21:148.e1-148.e4. http://dx.doi.org/10.1016/j.cmi.2014.07.008.
22. Borgia S, Lastovetska O, Richardson D, Eshaghi A, Xiong J, Chung C, Baqi M, McGeer A, Ricci G, Sawicki R, Pantelidis R, Low DE, Patel SN, Melano RG. 2012. Outbreak of carbapenem-resistant Enterobacteriaceae containing blaNDM-1, Ontario, Canada. Clin Infect Dis 55:e109-e117. http://dx.doi.org/10.1093/cid/cis737.
23. Tijet N, Richardson D, MacMullin G, Patel SN, Melano RG. 2015. Characterization of multiple NDM-1-producing Enterobacteriaceae isolates from the same patient. Antimicrob Agents Chemother 59:3648-3651. http://dx.doi.org/10.1128/AAC.04862-14.
24. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. 2011. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother 55:2420-2423. http://dx.doi.org/10.1128/AAC.01452-10.
25. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654-663. http://dx.doi.org/10.1128/AAC.01222-13.
26. Livermore DM, Andrews JM, Hawkey PM, Ho PL, Keness Y, Doi Y, Paterson D, Woodford N. 2012. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 67:1569-1577. http://dx.doi.org/10.1093/jac/dks088.
27. Souli M, Kontopidou FV, Papadomichelakis E, Galani I, Armaganidis A, Giamarellou H. 2008. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek university hospital. Clin Infect Dis 46:847-854. http://dx.doi.org/10.1086/528719.
28. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. 2009. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 64:233-235. http://dx.doi.org/10.1016/j.diagmicrobio.2009.02.004.